RxDoctor Payments Data

Lynn Canavan, MD

Surgical Oncology · Plano, TXNPI 1760441430

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (49.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Tactile Systems Technology Inc accounts for 85.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $8,896 and has fallen 98.9% since, to $100 in 2025.

$10,591in general payments, 2019–2025

Across 59 payments — averaging $179.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tactile Systems Technology Inc$9K
  • Myriad Genetic Laboratories, Inc.$653
  • Endomagnetics Ltd$255
  • Bone Support Inc.$146
  • Johnson & Johnson$125
  • Leica Microsystems Inc.$50
  • plus $274 from 10 others

What the payments were for

  • Speaking & faculty fees$3,60034%
  • Travel & lodging$5,23949%
  • Food & beverage$1,75217%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,591 in reported general payments places this provider in the 80th percentile of 191 surgical oncology providers in Texas.

See all surgical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$490,134
Medicare patients
295
Services billed
1,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole436$4,695
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen224$1,487
Tamoxifen Citrate71$1,424
Doxycycline Monohydrate84$1,399
Letrozole25$717
Ondansetron Hcl179$534
Cephalexin15$420
Venlafaxine Hcl ErVenlafaxine Hcl16$114
Cyclobenzaprine Hcl12$113
Tramadol Hcl16$49
Promethazine Hcl14$43

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →